Iranian Journal of Psychiatry and Behavioral Sciences

Published by: Kowsar

Drug Attitude Inventory in Patients with Bipolar Disorder: Psychometric Properties

Behnam Shariati 1 , Amir Shabani 2 , * , Elmira Ariana-Kia 3 , Masoud Ahmadzad-Asl 2 , Kaveh Alavi 4 , Zohreh Mousavi Behbahani 4 , Mohammad Reza Ghasemzadeh 5 , Sahar Hasani 4 , Zahra Ghiasi 6 , Fatemeh Kashaninasab 1 , Soodeh Tajik Esmaeeli 4 , Mohammad Reza Najjarzadegan 4 , Amin Kheirolahi 4 , Mahboobeh Beihaghi 4 , Seyed Vahid Shariat 7 and Shabnam Nohesara 4
Authors Information
1 Department of Psychiatry, Rasoul-e-Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
2 Mental Health Research Center, Mood Disorders Research Group, Iran University of Medical Sciences, Tehran, Iran
3 Department of Clinical Psychology, School of Education and Psychology, Shiraz University, Shiraz, Iran
4 Department of Psychiatry, Iran Psychiatric Hospital, Tehran, Iran
5 Department of Psychiatry, AJA University of Medical Sciences, Tehran, Iran
6 Department of Psychiatry, Zahedan University of Medical Sciences, Zahedan, Iran
7 Mental Health Research Center, Department of Psychiatry, Iran Psychiatric Hospital, Tehran, Iran
Article information
  • Iranian Journal of Psychiatry and Behavioral Sciences: September 2018, 12 (3); e9831
  • Published Online: July 21, 2018
  • Article Type: Original Article
  • Received: November 27, 2016
  • Revised: October 11, 2017
  • Accepted: December 16, 2017
  • DOI: 10.5812/ijpbs.9831

To Cite: Shariati B , Shabani A, Ariana-Kia E , Ahmadzad-Asl M , Alavi K , et al. Drug Attitude Inventory in Patients with Bipolar Disorder: Psychometric Properties, Iran J Psychiatry Behav Sci. 2018 ; 12(3):e9831. doi: 10.5812/ijpbs.9831.

Abstract
Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Fassassi S, Vandeleur C, Aubry JM, Castelao E, Preisig M. Prevalence and correlates of DSM-5 bipolar and related disorders and hyperthymic personality in the community. J Affect Disord. 2014;167:198-205. doi: 10.1016/j.jad.2014.06.004. [PubMed: 24995887].
  • 2. Sharifi V, Amin-Esmaeili M, Hajebi A, Motevalian A, Radgoodarzi R, Hefazi M, et al. Twelve-month prevalence and correlates of psychiatric disorders in Iran: the Iranian Mental Health Survey, 2011. Arch Iran Med. 2015;18(2):76-84. [PubMed: 25644794].
  • 3. Najt P, Perez J, Sanches M, Peluso MA, Glahn D, Soares JC. Impulsivity and bipolar disorder. Eur Neuropsychopharmacol. 2007;17(5):313-20. doi: 10.1016/j.euroneuro.2006.10.002. [PubMed: 17140772].
  • 4. Chang K, Howe M, Gallelli K, Miklowitz D. Prevention of pediatric bipolar disorder: integration of neurobiological and psychosocial processes. Ann N Y Acad Sci. 2006;1094:235-47. doi: 10.1196/annals.1376.026. [PubMed: 17347355].
  • 5. Shabani A, Ahmadzad-Asl M, Zangeneh K, Teimurinejad S, Kokar S, Taban M, et al. Quality of life in patients with bipolar I disorder: is it related to disorder outcome? Acta Med Iran. 2013;51(6):386-93. [PubMed: 23852843].
  • 6. Pompili M, Gonda X, Serafini G, Innamorati M, Sher L, Amore M, et al. Epidemiology of suicide in bipolar disorders: a systematic review of the literature. Bipolar Disord. 2013;15(5):457-90. doi: 10.1111/bdi.12087. [PubMed: 23755739].
  • 7. Shabani A, Teimurinejad S, Kokar S, Ahmadzad Asl M, Shariati B, Mousavi Behbahani Z, et al. Suicide Risk Factors in Iranian Patients With Bipolar Disorder: A 21- Month Follow-Up From BDPF Study. Iran J Psychiatry Behav Sci. 2013;7(1):16-23. [PubMed: 24644495]. [PubMed Central: PMC3939979].
  • 8. Ilgen MA, Bohnert AS, Ignacio RV, McCarthy JF, Valenstein MM, Kim HM, et al. Psychiatric diagnoses and risk of suicide in veterans. Arch Gen Psychiatry. 2010;67(11):1152-8. doi: 10.1001/archgenpsychiatry.2010.129. [PubMed: 21041616].
  • 9. Colom F, Vieta E, Martinez-Aran A, Reinares M, Benabarre A, Gasto C. Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry. 2000;61(8):549-55. doi: 10.4088/JCP.v61n0802. [PubMed: 10982196].
  • 10. Bengesser SA, Reininghaus B, Birner A, Lackner N, Kapfhammer HP, Reininghaus EZ. [Bipolar disorder and compliance]. Fortschr Neurol Psychiatr. 2013;81(7):398-400. doi: 10.1055/s-0033-1335380. [PubMed: 23856945].
  • 11. Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry. 2002;63(5):384-90. doi: 10.4088/JCP.v63n0502. [PubMed: 12019661].
  • 12. Kampman O, Laippala P, Vaananen J, Koivisto E, Kiviniemi P, Kilkku N, et al. Indicators of medication compliance in first-episode psychosis. Psychiatry Res. 2002;110(1):39-48. doi: 10.1016/S0165-1781(02)00030-6. [PubMed: 12007592].
  • 13. Mutsatsa SH, Joyce EM, Hutton SB, Webb E, Gibbins H, Paul S, et al. Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatr Scand. 2003;108(6):439-46. doi: 10.1046/j.0001-690X.2003.00193.x. [PubMed: 14616225].
  • 14. Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, Centorrhino F, et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res. 2006;83(1):53-63. doi: 10.1016/j.schres.2005.10.016. [PubMed: 16529910].
  • 15. Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA, et al. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008;69(1):106-13. doi: 10.4088/JCP.v69n0114. [PubMed: 18312044].
  • 16. Fischel T, Krivoy A, Kotlarov M, Zemishlany Z, Loebstein O, Jacoby H, et al. The interaction of subjective experience and attitudes towards specific antipsychotic-related adverse effects in schizophrenia patients. Eur Psychiatry. 2013;28(6):340-3. doi: 10.1016/j.eurpsy.2012.06.005. [PubMed: 22999435].
  • 17. Dolder CR, Lacro JP, Warren KA, Golshan S, Perkins DO, Jeste DV. Brief evaluation of medication influences and beliefs: development and testing of a brief scale for medication adherence. J Clin Psychopharmacol. 2004;24(4):404-9. doi: 10.1097/01.jcp.0000130554.63254.3a. [PubMed: 15232332].
  • 18. Naber D, Karow A, Lambert M. Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand Suppl. 2005;(427):29-34. doi: 10.1111/j.1600-0447.2005.00542.x. [PubMed: 15943008].
  • 19. Nielsen RE, Lindstrom E, Nielsen J, Levander S. DAI-10 is as good as DAI-30 in schizophrenia. Eur Neuropsychopharmacol. 2012;22(10):747-50. doi: 10.1016/j.euroneuro.2012.02.008. [PubMed: 22440974].
  • 20. Townsend L, Floersch J, Findling RL. Adolescent attitudes toward psychiatric medication: the utility of the Drug Attitude Inventory. J Child Psychol Psychiatry. 2009;50(12):1523-31. doi: 10.1111/j.1469-7610.2009.02113.x. [PubMed: 19686336]. [PubMed Central: PMC2804771].
  • 21. Gaebel W, Riesbeck M, von Wilmsdorff M, Burns T, Derks EM, Kahn RS, et al. Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol. 2010;20(5):310-6. doi: 10.1016/j.euroneuro.2010.02.001. [PubMed: 20202800].
  • 22. Tamaji A, Sakai A, Sato M, Ikema Y, Matsuzaki K, Tabuse H, et al. [Development of clinical pharmacy services to improve drug adherence in psychiatric hospital patients]. Yakugaku Zasshi. 2010;130(11):1565-72. doi: 10.1248/yakushi.130.1565. [PubMed: 21048417].
  • 23. Liu-Seifert H, Osuntokun OO, Godfrey JL, Feldman PD. Patient perspectives on antipsychotic treatments and their association with clinical outcomes. Patient Prefer Adherence. 2010;4:369-77. [PubMed: 21049089]. [PubMed Central: PMC2962402].
  • 24. Tay SE. Compliance therapy: an intervention to improve inpatients' attitudes toward treatment. J Psychosoc Nurs Ment Health Serv. 2007;45(6):29-37. [PubMed: 17601158].
  • 25. Cheng HL, Yu YW. [Validation of the Chinese version of "the Drug Attitude Inventory"]. Kaohsiung J Med Sci. 1997;13(6):370-7. [PubMed: 9251303].
  • 26. Shabani A, Taheri A, Azadforouz S, Abbasi CN, Mousavi Z, Zangeneh K, et al. Bipolar Disorder Patients Follow-up (BDPF): methods and materials. J Res Med Sci. 2010;15(4):229-34. [PubMed: 21526087]. [PubMed Central: PMC3082809].
  • 27. Kozma CM, Dickson M, Phillips AL, Meletiche DM. Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis. Patient Prefer Adherence. 2013;7:509-16. doi: 10.2147/PPA.S40736. [PubMed: 23807840]. [PubMed Central: PMC3685450].
  • 28. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13(1):177-83. doi: 10.2147/PPA.S40736. [PubMed: 6133297].
  • 29. Rossi A, Arduini L, De Cataldo S, Stratta P. [Subjective response to neuroleptic medication: a validation study of the Italian version of the Drug Attitude Inventory (DAI)]. Epidemiol Psichiatr Soc. 2001;10(2):107-14. doi: 10.1017/S1121189X00005182. [PubMed: 11526792].
  • 30. Robles Garcia R, Salazar Alvarado V, Paez Agraz F, Ramirez Barreto F. [Assessment of drug attitudes in patients with schizophrenia: psychometric properties of the DAI Spanish version]. Actas Esp Psiquiatr. 2004;32(3):138-42. [PubMed: 15168263].
  • 31. Yoon BH, Bahk WM, Lee KU, Hong CH, Ahn JK, Kim MK. Psychometric properties of korean version of drug attitude inventory (KDAI-10). Korean J Psychopharmacol. 2005;16:480-7.
  • 32. Norman GR, Streiner DL. Biostatistics: The Bare Essentials. 2nd ed. Hamilton, Ontario, Canada: B. C. Decker; 2000.
  • 33. Rocca P, Crivelli B, Marino F, Mongini T, Portaleone F, Bogetto F. Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia. Compr Psychiatry. 2008;49(2):170-6. doi: 10.1016/j.comppsych.2007.08.013. [PubMed: 18243890].
  • 34. Day JC, Bentall RP, Roberts C, Randall F, Rogers A, Cattell D, et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry. 2005;62(7):717-24. doi: 10.1001/archpsyc.62.7.717. [PubMed: 15997012].
  • 35. Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA. Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull. 2009;35(2):336-46. doi: 10.1093/schbul/sbn067. [PubMed: 18586692]. [PubMed Central: PMC2659303].
  • 36. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892-909. [PubMed: 12416599].
  • 37. Yang J, Ko YH, Paik JW, Lee MS, Han C, Joe SH, et al. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia. Schizophr Res. 2012;134(2-3):226-31. doi: 10.1016/j.schres.2011.11.008. [PubMed: 22133906].
  • 38. Kikkert MJ, Koeter MW, Dekker JJ, Burti L, Robson D, Puschner B, et al. The predictive validity of subjective adherence measures in patients with schizophrenia. Int J Methods Psychiatr Res. 2011;20(2):73-81. doi: 10.1002/mpr.335. [PubMed: 21557378].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments